Evidence map›Paper›PMID 32708023›Full record

ReviewBiomedicines2020

Curses or Cures: A Review of the Numerous Benefits Versus the Biosecurity Concerns of Conotoxin Research.

Walden E Bjørn-Yoshimoto, Iris Bea L Ramiro, Mark Yandell, J Michael McIntosh, Baldomero M Olivera, Lars Ellgaard, Helena Safavi-Hemami

Open access · goldAbstract readReview
In one paragraph

Review in Biomedicines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Systemic antihyperalgesic effect of a novel conotoxin fromFrontiers in pain research (Lausanne, Switzerland) · 2024
    Article
  10. Review
  11. Review
  12. Cone snail species off the Brazilian coast and their venoms: a review and update.The journal of venomous animals and toxins including tropical diseases · 2023
    Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Walden E Bjørn-YoshimotoDepartment of Biomedical Sciences, University of Copenhagen, 2200 Copenhagen N, Denmark.ORCID 0000-0003-1019-9239
Iris Bea L RamiroDepartment of Biomedical Sciences, University of Copenhagen, 2200 Copenhagen N, Denmark.ORCID 0000-0003-3971-3107
Mark YandellEccles Institute of Human Genetics, University of Utah, Salt Lake City, UT 84112, USA.
J Michael McIntoshSchool of Biological Sciences, University of Utah, Salt Lake City, UT 84112, USA.
Baldomero M OliveraSchool of Biological Sciences, University of Utah, Salt Lake City, UT 84112, USA.
Lars EllgaardDepartment of Biology, Linderstrøm-Lang Centre for Protein Science, University of Copenhagen, 2200 Copenhagen N, Denmark.ORCID 0000-0002-7018-0137
Helena Safavi-HemamiDepartment of Biomedical Sciences, University of Copenhagen, 2200 Copenhagen N, Denmark.ORCID 0000-0002-1984-2721
University of Copenhagen · DKUniversity of Utah · US

Funding

Utah Center for Clinical and Translational ScienceUL1TR002538 · NCATS · UNIVERSITY OF UTAH · PI HESS, RACHEL, MAJERSIK, JENNIFER JUHL · 2018 to 2022
$26.0M
Novel nAChR-Targeted PeptidesR01GM103801 · NIGMS · UNIVERSITY OF UTAH · PI MCINTOSH, J MICHAEL · 2012 to 2019
$2.4M
Development and Application of Nicotinic Acetylcholine Receptor Targeted Peptides for Biomedical ResearchR35GM136430 · NIGMS · UNIVERSITY OF UTAH · PI MCINTOSH, J MICHAEL · 2020 to 2024
$2.3M
Life history-guided drug discovery from venomous marine snailsR01GM122869 · NIGMS · UNIVERSITY OF UTAH · PI OLIVERA, BALDOMERO M, YANDELL, MARK DOUGLAS · 2018 to 2022
$1.5M
NCATS NIH HHS UL1 TR002538NIGMS NIH HHS R01 GM103801NIGMS NIH HHS R01 GM122869NIGMS NIH HHS R35 GM136430NIH HHS GM103801NIH HHS GM122869NIH HHS GM136430
6 · The paper itself

Abstract

Conotoxins form a diverse group of peptide toxins found in the venom of predatory marine cone snails. Decades of conotoxin research have provided numerous measurable scientific and societal benefits. These include their use as a drug, diagnostic agent, drug leads, and research tools in neuroscience, pharmacology, biochemistry, structural biology, and molecular evolution. Human envenomations by cone snails are rare but can be fatal. Death by envenomation is likely caused by a small set of toxins that induce muscle paralysis of the diaphragm, resulting in respiratory arrest. The potency of these toxins led to concerns regarding the potential development and use of conotoxins as biological weapons. To address this, various regulatory measures have been introduced that limit the use and access of conotoxins within the research community. Some of these regulations apply to all of the ≈200,000 conotoxins predicted to exist in nature of which less than 0.05% are estimated to have any significant toxicity in humans. In this review we provide an overview of the many benefits of conotoxin research, and contrast these to the perceived biosecurity concerns of conotoxins and research thereof.

Indexed as

biomedicinebiosecuritycone snailconopeptideconotoxindrugsenvenomationsfatalitiesvenom

Identifiers

PMID32708023
PMCPMC7460000
OpenAlexW3044792634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.